NUC-1031 in biliary tract cancer: from bench to bedside and back?
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04080-6
Abstract: In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and… read more here.
Keywords: biliary tract; 1031 biliary; tract cancer; nuc 1031 ... See more keywords
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps5612
Abstract: TPS5612Background: Patients with platinum-resistant ovarian cancer, following ≥3 lines of chemotherapy have limited treatment options. NUC-1031, a phosphoramidate transformation of gemcitabine, is ... read more here.
Keywords: resistant ovarian; nuc 1031; ovarian cancer; platinum resistant ... See more keywords
ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.tps544
Abstract: TPS544Background: The UK ABC-02 study established cisplatin and gemcitabine as the reference regimen for first-line treatment of patients (pts) with advanced biliary tract cancers (BTCs) (median overall survival (OS): 11.7 months). No clinical studies since… read more here.
Keywords: biliary tract; study; nuc 1031; tract cancers ... See more keywords
NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps4156
Abstract: TPS4156 Background: Cisplatin and gemcitabine (CisGem) is the global standard of care for 1st-line treatment of patients (pts) with advanced biliary tract cancer (BTC). No agents have regulatory approval for this disease. CisGem achieves an… read more here.
Keywords: line treatment; nuc 1031; cancer; cisplatin ... See more keywords
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.tps351
Abstract: TPS351Background: Biliary tract cancer (BTC) carries a poor prognosis and no first-line treatments are approved. The accepted global standard of care is gemcitabine + cisplatin (GemCis). NUC-1031 i... read more here.
Keywords: biliary tract; tract cancer; nuc 1031; first line ... See more keywords
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2020-0247
Abstract: Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal… read more here.
Keywords: biliary tract; cisplatin; nuc 1031; gemcitabine cisplatin ... See more keywords